ABBVHealthcare · Drug Manufacturers - GeneralThe 31 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $280 — +14.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Issuance (50): The company has been issuing shares or taking on financing, diluting existing holders.
Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +14.2% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 July 2026 | Barclays | Maintains | Overweight | $275 → $300 |
| 22 July 2026 | Canaccord Genuity | Maintains | Buy | $273 → $282 |
| 15 July 2026 | Citigroup | Maintains | Neutral | $230 → $260 |
| 15 July 2026 | Citigroup | Maintains | Neutral | — |
| 13 July 2026 | BMO Capital | Maintains | Outperform | — |
| 13 July 2026 | BMO Capital | Maintains | Outperform | $258 → $300 |
| 13 July 2026 | UBS | Maintains | Neutral | — |
| 13 July 2026 | UBS | Maintains | Neutral | $230 → $260 |
| 10 July 2026 | B of A Securities | Maintains | Buy | $234 → $276 |
| 10 July 2026 | B of A Securities | Maintains | Buy | — |
| 10 July 2026 | RBC Capital | Maintains | Outperform | — |
| 10 July 2026 | RBC Capital | Maintains | Outperform | $260 → $280 |
| 10 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 10 July 2026 | Wells Fargo | Maintains | Overweight | $260 → $295 |
| 9 July 2026 | Guggenheim | Maintains | Buy | — |
| 9 July 2026 | Guggenheim | Maintains | Buy | $249 → $261 |
| 9 July 2026 | JP Morgan | Maintains | Overweight | — |
| 9 July 2026 | JP Morgan | Maintains | Overweight | $260 → $280 |
| 6 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $240 → $265 |
| 6 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 11% of US stocks
Cheaper than 19% of US stocks
Cheaper than 99% of US stocks
Cheaper than 21% of US stocks
Higher than 55% of US stocks
Higher than 93% of US stocks
Higher than 85% of US stocks
Higher than 92% of US stocks
Higher than 70% of US stocks
Higher than 10% of US stocks
Higher than 67% of US stocks
Higher than 60% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABBV appears on the weeks it earns a place.
On its Q2 earnings call, AbbVie raised its 2026 revenue guidance, citing growth from Skyrizi, Rinvoq, and its neuroscience portfolio, while the Apogee deal trimmed EPS guidance and increased R&D spending.
Why it matters — ABBV watchers would care because the call shows both upgraded revenue expectations and the earnings-dilutive, R&D-raising impact of the Apogee acquisition.
AbbVie shares reached a 52-week high of $267.47 on June 29 but fell 6.2% over the following five days despite strong Q2 earnings. Rinvoq sales grew 24.5% year-over-year and 19.2% quarter-over-quarter to about $2.53 billion in Q2, and the article's author remains bullish on the stock.
Why it matters — ABBV watchers would care because strong Q2 results and continued Rinvoq growth are key indicators of the company's performance, while the article's bullish stance suggests confidence in new catalysts ahead.
AbbVie's stock declined after the company released a second-quarter earnings report that missed consensus earnings estimates, raising concerns among investors.
Why it matters — An earnings miss can pressure AbbVie's stock price and signal potential underlying business challenges that shareholders should monitor.
Seeking Alpha published a transcript of AbbVie Inc.'s second-quarter 2026 earnings call.
Why it matters — Earnings call transcripts provide investors with direct insight into management's commentary on AbbVie's recent financial performance and outlook.
AbbVie reported second-quarter earnings and revenue that topped analysts' estimates, driven by strong immunology drug sales. However, the company lowered its 2026 earnings-per-share outlook due to its Apogee deal, causing the stock to fall.
Why it matters — ABBV watchers would care because the stock declined despite a quarterly beat, as the lower 2026 EPS guidance tied to the Apogee deal introduced fresh uncertainty about the company's medium-term profit trajectory.
The 31 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $280, with estimates ranging from $200 to $328. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 31 analysts covering AbbVie, Inc., 24 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 91 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, AbbVie, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 31 analysts implies +14.2% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 91 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $328 over the next 12 months.
AbbVie, Inc. returned +29.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide.
The most recent item we track (Zacks Investment Research, 3 Aug 2026): "ABBV Q2 Earnings Call Balances Growth With Apogee Dilution". On its Q2 earnings call, AbbVie raised its 2026 revenue guidance, citing growth from Skyrizi, Rinvoq, and its neuroscience portfolio, while the Apogee deal trimmed EPS guidance and increased R&D spending.
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in rheumatology, gastroenterology, dermatology, and related areas. In oncology, it provides therapies such as Imbruvica, Venclexta, Elahere, Epkinly, and Emrelis targeting blood cancers, lymphoma, and lung cancer. AbbVie Inc. also addresses virology with Mavyret for hepatitis C, neuroscience for neurological disorders like Parkinson's, and additional areas including metabolic diseases, cystic fibrosis complications, endometriosis pain, irritable bowel syndrome, chronic constipation, and pancreatic enzyme therapy with Creon, alongside aesthetics products like Botox and Linzess/Constella. Founded in 2013 and headquartered in North Chicago, Illinois, AbbVie Inc. plays a vital role in the healthcare sector by delivering solutions for complex, chronic, and serious health conditions.
CEO Mr. Robert A. Michael C.P.A. · 57,000 employees · United States · https://www.abbvie.com